United States Tardive Dyskinesia (TD) Treatment Drugs Market was valued at USD 0.27 Billion in 2022 and is projected to reach USD 1.10 Billion by 2030, growing at a CAGR of 19.8% from 2024 to 2030.
Tardive Dyskinesia (Td) Is A Neurological Disorder Characterized By Involuntary, Repetitive Movements, Often Resulting From Prolonged Use Of Certain Medications, Particularly Antipsychotics Prescribed For Psychiatric Conditions Like Schizophrenia And Bipolar Disorder. Symptoms Include Grimacing, Tongue Movements, Lip Smacking, And Rapid Eye Blinking. In Some Cases, Rapid Movements Of The Arms, Legs, And Trunk Are Also Observed.
The U.S. Td Treatment Market Has Experienced Significant Growth In Recent Years. In 2017, The U.S. Food And Drug Administration (Fda) Approved Ingrezza (Valbenazine) Capsules, Marking The First Drug Approved For Td Treatment. This Approval Was A Pivotal Moment, Offering Patients A Targeted Therapy Option. Clinical Trials Demonstrated That Participants Receiving Valbenazine Had A Notable Improvement In The Severity Of Abnormal Involuntary Movements Compared To Those Who Received A Placebo.
Following This, In 2024, The Fda Approved Austedo Xr (Deutetrabenazine) Extended-Release Tablets, A New Once-Daily Formulation For The Treatment Of Td And Chorea Associated With Huntington'S Disease In Adults. This Approval Expanded The Arsenal Of Available Treatments, Providing More Options For Personalized Patient Care. Clinical Studies Have Shown That Deutetrabenazine Significantly Reduces Involuntary Movements In Td Patients, With A Favorable Safety And Tolerability Profile.
Market Dynamics Indicate A Robust Growth Trajectory For Td Treatment Drugs. The U.S. Market Is Expected To Reach Approximately $6.4 Billion By 2031, Up From $3.06 Billion In 2023, Exhibiting A Compound Annual Growth Rate (Cagr) Of 9.8% During The Forecast Period. This Growth Is Driven By Increasing Clinical Approvals And A Heightened Awareness Of Td Among Healthcare Professionals And Patients.
From An Industry Perspective, There Is A Growing Emphasis On Developing Drugs That Not Only Effectively Manage Td Symptoms But Also Offer Improved Safety Profiles And Patient Compliance. The Introduction Of Extended-Release Formulations, Such As Austedo Xr, Addresses The Need For Simplified Dosing Regimens, Which Can Enhance Treatment Adherence. Additionally, The Focus Is On Drugs That Selectively Target The Underlying Mechanisms Of Td, Thereby Minimizing Potential Side Effects Associated With Broader-Acting Medications.
Moreover, The Industry Is Witnessing A Trend Towards Personalized Medicine, Where Treatments Are Tailored Based On Individual Patient Characteristics, Including Genetic Profiles And Specific Symptomatology. This Approach Necessitates Collaboration Between Pharmaceutical Companies, Healthcare Providers, And Researchers To Develop Biomarkers That Can Predict Treatment Response And Guide Therapy Decisions.
In Conclusion, The U.S. Td Treatment Drugs Market Is Poised For Substantial Growth, Driven By Innovative Drug Developments And A Deeper Understanding Of The Disorder. The Industry'S Focus On Safety, Efficacy, And Patient-Centric Approaches Aligns With The Evolving Landscape Of Neurological Disorder Treatments, Promising Improved Quality Of Life For Those Affected By Td.
Get an In-Depth Research Analysis of the US Tardive Dyskinesia (TD) Treatment Drugs Market Size And Forecast [2025-2032]
Â
Neurocrine Biosciences
Inc
Teva Pharmaceutical Industries
Pfizer Inc
Biogen
Novartis AG
AstraZeneca
GlaxoSmithKline plc.
Bayer AG
Sanofi
Â
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US Tardive Dyskinesia (TD) Treatment Drugs Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US Tardive Dyskinesia (TD) Treatment Drugs Market
Oral Medications
Injectable Medications
Topical Medications
Dopamine-Depleting Agents
Dopamine-Receptor Agonists
GABAergic Agents
Glutamate Modulators
Pharmacological Therapy
Non-Pharmacological Therapy
Oral
Injectable
Intravenous
Hospitals
Clinics
Home Care Settings
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Tardive Dyskinesia (TD) Treatment Drugs Market Research Analysis
1. Introduction of the US Tardive Dyskinesia (TD) Treatment Drugs Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US Tardive Dyskinesia (TD) Treatment Drugs Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US Tardive Dyskinesia (TD) Treatment Drugs Market, By Type
6. US Tardive Dyskinesia (TD) Treatment Drugs Market, By Application
7. US Tardive Dyskinesia (TD) Treatment Drugs Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US Tardive Dyskinesia (TD) Treatment Drugs Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/